Injectable anti-malarials revisited

discovery and development of new agents to protect against malaria

Fiona Macintyre, Hanu Ramachandruni, Jeremy N. Burrows, René Holm, Anna Thomas, Jörg J. Möhrle, Stephan Duparc, Rob Hooft van Huijsduijnen, Brian Greenwood, Winston E. Gutteridge, Timothy N.C. Wells, Wiweka Kaszubska

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

Over the last 15 years, the majority of malaria drug discovery and development efforts have focused on new molecules and regimens to treat patients with uncomplicated or severe disease. In addition, a number of new molecular scaffolds have been discovered which block the replication of the parasite in the liver, offering the possibility of new tools for oral prophylaxis or chemoprotection, potentially with once-weekly dosing. However, an intervention which requires less frequent administration than this would be a key tool for the control and elimination of malaria. Recent progress in HIV drug discovery has shown that small molecules can be formulated for injections as native molecules or pro-drugs which provide protection for at least 2 months. Advances in antibody engineering offer an alternative approach whereby a single injection could potentially provide protection for several months. Building on earlier profiles for uncomplicated and severe malaria, a target product profile is proposed here for an injectable medicine providing long-term protection from this disease. As with all of such profiles, factors such as efficacy, cost, safety and tolerability are key, but with the changing disease landscape in Africa, new clinical and regulatory approaches are required to develop prophylactic/chemoprotective medicines. An overall framework for these approaches is suggested here
OriginalsprogEngelsk
TidsskriftMalaria Journal
Vol/bind17
Udgave nummer1
DOI
StatusUdgivet - 2018

Citer dette

Macintyre, F., Ramachandruni, H., Burrows, J. N., Holm, R., Thomas, A., Möhrle, J. J., ... Kaszubska, W. (2018). Injectable anti-malarials revisited: discovery and development of new agents to protect against malaria. Malaria Journal, 17(1). https://doi.org/10.1186/s12936-018-2549-1
Macintyre, Fiona ; Ramachandruni, Hanu ; Burrows, Jeremy N. ; Holm, René ; Thomas, Anna ; Möhrle, Jörg J. ; Duparc, Stephan ; Hooft van Huijsduijnen, Rob ; Greenwood, Brian ; Gutteridge, Winston E. ; Wells, Timothy N.C. ; Kaszubska, Wiweka. / Injectable anti-malarials revisited : discovery and development of new agents to protect against malaria. I: Malaria Journal. 2018 ; Bind 17, Nr. 1.
@article{ec4691fd01ba48c0a8b11274d01343c6,
title = "Injectable anti-malarials revisited: discovery and development of new agents to protect against malaria",
abstract = "Over the last 15 years, the majority of malaria drug discovery and development efforts have focused on new molecules and regimens to treat patients with uncomplicated or severe disease. In addition, a number of new molecular scaffolds have been discovered which block the replication of the parasite in the liver, offering the possibility of new tools for oral prophylaxis or chemoprotection, potentially with once-weekly dosing. However, an intervention which requires less frequent administration than this would be a key tool for the control and elimination of malaria. Recent progress in HIV drug discovery has shown that small molecules can be formulated for injections as native molecules or pro-drugs which provide protection for at least 2 months. Advances in antibody engineering offer an alternative approach whereby a single injection could potentially provide protection for several months. Building on earlier profiles for uncomplicated and severe malaria, a target product profile is proposed here for an injectable medicine providing long-term protection from this disease. As with all of such profiles, factors such as efficacy, cost, safety and tolerability are key, but with the changing disease landscape in Africa, new clinical and regulatory approaches are required to develop prophylactic/chemoprotective medicines. An overall framework for these approaches is suggested here",
author = "Fiona Macintyre and Hanu Ramachandruni and Burrows, {Jeremy N.} and Ren{\'e} Holm and Anna Thomas and M{\"o}hrle, {J{\"o}rg J.} and Stephan Duparc and {Hooft van Huijsduijnen}, Rob and Brian Greenwood and Gutteridge, {Winston E.} and Wells, {Timothy N.C.} and Wiweka Kaszubska",
year = "2018",
doi = "10.1186/s12936-018-2549-1",
language = "English",
volume = "17",
journal = "Malaria Journal",
issn = "1475-2875",
publisher = "BioMed Central",
number = "1",

}

Macintyre, F, Ramachandruni, H, Burrows, JN, Holm, R, Thomas, A, Möhrle, JJ, Duparc, S, Hooft van Huijsduijnen, R, Greenwood, B, Gutteridge, WE, Wells, TNC & Kaszubska, W 2018, 'Injectable anti-malarials revisited: discovery and development of new agents to protect against malaria', Malaria Journal, bind 17, nr. 1. https://doi.org/10.1186/s12936-018-2549-1

Injectable anti-malarials revisited : discovery and development of new agents to protect against malaria. / Macintyre, Fiona; Ramachandruni, Hanu; Burrows, Jeremy N.; Holm, René; Thomas, Anna; Möhrle, Jörg J.; Duparc, Stephan; Hooft van Huijsduijnen, Rob; Greenwood, Brian; Gutteridge, Winston E.; Wells, Timothy N.C.; Kaszubska, Wiweka.

I: Malaria Journal, Bind 17, Nr. 1, 2018.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Injectable anti-malarials revisited

T2 - discovery and development of new agents to protect against malaria

AU - Macintyre, Fiona

AU - Ramachandruni, Hanu

AU - Burrows, Jeremy N.

AU - Holm, René

AU - Thomas, Anna

AU - Möhrle, Jörg J.

AU - Duparc, Stephan

AU - Hooft van Huijsduijnen, Rob

AU - Greenwood, Brian

AU - Gutteridge, Winston E.

AU - Wells, Timothy N.C.

AU - Kaszubska, Wiweka

PY - 2018

Y1 - 2018

N2 - Over the last 15 years, the majority of malaria drug discovery and development efforts have focused on new molecules and regimens to treat patients with uncomplicated or severe disease. In addition, a number of new molecular scaffolds have been discovered which block the replication of the parasite in the liver, offering the possibility of new tools for oral prophylaxis or chemoprotection, potentially with once-weekly dosing. However, an intervention which requires less frequent administration than this would be a key tool for the control and elimination of malaria. Recent progress in HIV drug discovery has shown that small molecules can be formulated for injections as native molecules or pro-drugs which provide protection for at least 2 months. Advances in antibody engineering offer an alternative approach whereby a single injection could potentially provide protection for several months. Building on earlier profiles for uncomplicated and severe malaria, a target product profile is proposed here for an injectable medicine providing long-term protection from this disease. As with all of such profiles, factors such as efficacy, cost, safety and tolerability are key, but with the changing disease landscape in Africa, new clinical and regulatory approaches are required to develop prophylactic/chemoprotective medicines. An overall framework for these approaches is suggested here

AB - Over the last 15 years, the majority of malaria drug discovery and development efforts have focused on new molecules and regimens to treat patients with uncomplicated or severe disease. In addition, a number of new molecular scaffolds have been discovered which block the replication of the parasite in the liver, offering the possibility of new tools for oral prophylaxis or chemoprotection, potentially with once-weekly dosing. However, an intervention which requires less frequent administration than this would be a key tool for the control and elimination of malaria. Recent progress in HIV drug discovery has shown that small molecules can be formulated for injections as native molecules or pro-drugs which provide protection for at least 2 months. Advances in antibody engineering offer an alternative approach whereby a single injection could potentially provide protection for several months. Building on earlier profiles for uncomplicated and severe malaria, a target product profile is proposed here for an injectable medicine providing long-term protection from this disease. As with all of such profiles, factors such as efficacy, cost, safety and tolerability are key, but with the changing disease landscape in Africa, new clinical and regulatory approaches are required to develop prophylactic/chemoprotective medicines. An overall framework for these approaches is suggested here

U2 - 10.1186/s12936-018-2549-1

DO - 10.1186/s12936-018-2549-1

M3 - Journal article

VL - 17

JO - Malaria Journal

JF - Malaria Journal

SN - 1475-2875

IS - 1

ER -